Middle East

Established biopharmacy manufacturing campus in Mubadala, G42, Abu Dhabi

Mubadala Investment Company and G42 have signed an agreement to establish a new Biopharma Campus in Abu Dhabi.

The facility will “strengthen the regional supply chain” and focus on vaccines and treatments to support the UAE’s diversification program, the statement said.

Consider end-to-end manufacturing of biologics and host an anchor partnership with a contract manufacturing and development organization (CDMO).

The CDMO model allows manufacturers to work with multiple players to mitigate product risk and achieve economies of scale.

Biofferma Campus is also established by investing in multiple biopharmaceutical initiatives.

The agreement is part of Mubadala’s strategy to develop a sustainable healthcare and life sciences ecosystem within Abu Dhabi, the statement said.

“Global supply shortages and limited quantities of advanced manufacturing activities in the region have made biopharmacy a high-growth market (10% CAGR over the last five years), Mubadala’s preferred investment area within the life sciences sector. It became. “Added.

The ability of biopharmacy to deal with previously incurable conditions has also provided strong future growth potential.

Musabbeh Al Kaabi, CEO of UAE Investments in Mubadala, said:

Peng Xiao, Group CEO of G42, said: From a humble origin in the technology sector 10 years ago, these technologies are now being used in a variety of industries that focus on speed, scalability, innovation, and resilience. Pharmaceuticals and healthcare companies have great opportunities to leverage AI and cloud technology to improve their processes. “



https://gulfbusiness.com/mubadala-g42-to-set-up-biopharma-manufacturing-campus-in-abu-dhabi/ Established biopharmacy manufacturing campus in Mubadala, G42, Abu Dhabi

Show More
Back to top button